OncoGenex Pharmaceuticals, Inc. (OGXI) Posts Q4 Loss of 98c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts OGXI Hot Sheet
Join SI Premium – FREE
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) reported Q4 EPS of ($0.98), $0.37 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.86 million.
For earnings history and earnings-related data on OncoGenex Pharmaceuticals, Inc. (OGXI) click here.
For earnings history and earnings-related data on OncoGenex Pharmaceuticals, Inc. (OGXI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AIR Global sets first-ever dividend, $100M buyback amid business, cash strength
- Independent Bank (INDB) Tops Q3 EPS by 5c
- J.B. Hunt Transport Services (JBHT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
